Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic DC/Tumor Fusion Vaccine in Stage IV RCC
NCT00050323Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2002
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Allogeneic Dendritic Cell/Autologous Tumor Cell Fusion Vaccine in renal cell carcinoma (RCC), sponsored by Sanofi. Started Nov 2002; status: completed.
02
Drugs
Allogeneic Dendritic Cell/Autologous Tumor Cell Fusion Vaccine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00050323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050323.